- Home
- LARK vs NVCT Comparison
LARK vs NVCT Comparison
Compare LARK & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LARK | NVCT |
|---|---|---|
| Founded | 1885 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 167.0M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | LARK | NVCT |
|---|---|---|
| Price | $27.91 | $6.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 8.4K | ★ 85.8K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ 38.73 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $64,367,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.83 | ★ N/A |
| Revenue Growth | ★ 12.95 | N/A |
| 52 Week Low | $20.99 | $4.44 |
| 52 Week High | $29.56 | $11.52 |
Technical Indicators
Market Signals| Indicator | LARK | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 62.82 |
| Support Level | $27.26 | $5.77 |
| Resistance Level | $28.77 | $6.38 |
| Average True Range (ATR) | 0.92 | 0.33 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 39.57 | 95.59 |
Price Performance
Historical ComparisonAbout LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.